Bayer enters one of its most consequential weeks in years, with a Supreme Court hearing on glyphosate liability looming just days after shareholders gather for a virtual annual general meeting. The convergence of legal, political, and financial pressures leaves the German conglomerate navigating a narrow path between debt reduction and existential litigation risk.
A New Guard Takes the Helm
The supervisory board is set for a shake-up, with two new capital representatives proposed for election at today’s meeting. Marcel Smits, former CFO and strategy chief at agricultural giant Cargill, brings deep expertise in global supply chains. Alfred Stern, currently CEO of OMV, adds experience in sustainability and governance. They replace outgoing members Paul Achleitner and Colleen Goggins, whose terms expire at the close of the AGM. Analysts view the transition as a signal of commitment to the transformation agenda CEO Bill Anderson has championed since taking the reins.
The Legal Tightrope
Just four days after the shareholder vote, Bayer will argue before the US Supreme Court on April 27 over the fundamental question of glyphosate liability. The company is pursuing a multi-pronged strategy. It has established the “Modern Ag Alliance” (MAA), a lobbying group launched in 2024, to press Congress for a Roundup immunity clause in the next Farm Bill — a political end-run around tens of thousands of outstanding cancer lawsuits.
The legal push also leans on an executive order from President Trump mandating domestic production of crop protection chemicals, a directive Bayer has pledged to meet. The Supreme Court’s eventual ruling will shape the company’s financial trajectory for years to come.
Should investors sell immediately? Or is it worth buying Bayer?
Austerity for Shareholders
The dividend proposal for fiscal 2025 stands at €0.11 per share — the legal minimum. The message is unambiguous: debt reduction takes precedence over shareholder returns. Net financial debt stood at nearly €30 billion at year-end 2025, leaving little room for distributions.
Anderson’s “Dynamic Shared Ownership” restructuring program aims to streamline operations and embed AI-driven processes. The target is an operating margin approaching 30% by 2030, a significant climb from current levels. For the current year, Bayer forecasts currency-adjusted revenue between €45 billion and €47 billion, representing growth of zero to three percent. Management describes 2026 as a “year of stabilization,” with new pharmaceutical products expected to increasingly drive growth.
Market Sentiment and the Road Ahead
The stock trades around €40, down roughly 2.6% over the past week and about 18% below its 52-week high of €49.17. However, since hitting a trough in May 2025, shares have nearly doubled. The year-to-date gain stands at a robust 82%.
The AGM will vote on profit appropriation on Friday, setting the stage for Monday’s Supreme Court appearance. The interplay between legal clarity and financial discipline will determine whether Bayer can sustain its recovery — or whether the weight of litigation drags it back down.
Ad
Bayer Stock: Buy or Sell?! New Bayer Analysis from September 7 delivers the answer:
The latest Bayer figures speak for themselves: Urgent action needed for Bayer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from September 7.
Bayer: Buy or sell? Read more here...
